Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

BACKGROUND: The NGR-hTNF (asparagine–glycine–arginine–human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by selectively damaging tumour blood vessels. METHODS: Patients progressing after ⩾1 platinum/taxane-based regimen re...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lorusso, D, Scambia, G, Amadio, G, di Legge, A, Pietragalla, A, De Vincenzo, R, Masciullo, V, Di Stefano, M, Mangili, G, Citterio, G, Mantori, M, Lambiase, A, Bordignon, C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2012
Gaiak:
Translational Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3389423/
https://ncbi.nlm.nih.gov/pubmed/22644293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.233
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak